Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of CRC tumor organoids engineered with key driver mutations

ABSTRACT: RNA sequencing of CRC tumor organoids engineered with key driver mutations

PROVIDER: PRJNA856659 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20020334.fastq.gz	Fastqsanger.gz
	SRR20020335.fastq.gz	Fastqsanger.gz
	SRR20020336.fastq.gz	Fastqsanger.gz
	SRR20020337.fastq.gz	Fastqsanger.gz
	SRR20020338.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

RNA sequencing of CRC tumor organoids engineered with key driver mutations

Project description:We profiled CRC organoids engineered with different combinations of driver mutations. All organoids were derived from one mouse and then mutations were sequentially introduced by CRISPR Cas9

2022-09-16 | GSE207668 | GEO

Transcriptome and chromatin changes during CRC organoid outgrowth as proxy for metastatic outgrowth [bulkRNAseq_AKP]

Project description:Human engineered CRC organoids were equipped with the intestinal stem cell reporter STAR reflecting transcriptional activity of ASCL2. Bulk RNA-sequencing was performed on STAR+ and STAR- cells after 5 days and after 12 days.

2023-12-01 | GSE207070 | GEO

Transcriptome and chromatin changes during CRC organoid outgrowth as proxy for metastatic outgrowth [bulkRNAseq_AKPS]

2023-12-01 | GSE207069 | GEO

Transcriptome and chromatin changes during CRC organoid outgrowth as proxy for metastatic outgrowth [bulkATACseq_AKPS]

Project description:Human engineered CRC organoids were equipped with the intestinal stem cell reporter STAR reflecting transcriptional activity of ASCL2. Bulk ATAC-sequencing was performed on STAR populations after 5 days and after 12 days of plating single STAR+ or STAR- cells.

2023-12-01 | GSE207068 | GEO

RNA-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

Project description:To characterize the transcriptional changes acorss the CRC malignancy continum, wild type organoids (WT), ApcKO (A) and ApcKO::KrasG12D::Smad4KO::Trp53KO (AKSP) tumoroids were subjected to bulk RNA_seq. We then performed gene expression profiling analysis using data obtained from mRNA-seq of the indicated organoid lines.

2024-10-17 | GSE239754 | GEO

ATAC-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

Project description:To characterize changes in chromatin accessibility acorss the CRC malignancy continum, wild type organoids (WT), ApcKO (A) and ApcKO::KrasG12D::Smad4KO::Trp53KO (AKSP) tumoroids were subjected to bulk ATAC-seq. We then performed differential accessibility analysis using data obtained from ATAC-seq of the indicated organoid lines.

2024-10-17 | GSE239752 | GEO

GEMM CRC collection analysis

Project description:A collection of genetically engineered mouse models (GEMM) of colorectal cancer (CRC) were created, and primary tumors from these GEMMs were analyzed. Primary CRC tumors from these GEMMs were genotyped to confirm that they contain the core genetic lesions of interest, including APC, P53, KRAS, and BRAF. Primary tumors from GEMMs with combinations of lesions of interest were analyzed by whole genome expression, and their expression profiles were compared to determine how they segregate. Signatures were then generated from GEMM tumors of interest and compared to human clinical datasets with expression and outcome data. Primary tumors from CRC GEMMs with different combinations of mutant alleles of interested were generated and analyzed. Alleles include mutant forms of APC (A), P53 (P), KRAS (K) and BRAF (B).

2014-07-01 | E-GEOD-50794 | biostudies-arrayexpress

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [CRC]

Project description:Colorectal tumors are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumor progression but are burdened by exhaustion mechanisms fueled by the tumor microenvironment, which must be counteracted to achieve control. Here, we deployed a multidimensional approach to unravel the T cell functional landscape in tumor and peritumoral tissues from primary colorectal cancers and liver metastases. We found that T-cells are mainly localized at the front edge and that tumor-infiltrating T cells co-express multiple inhibitory receptors and highlighted CD39 as the major driver of exhaustion in both primary and metastatic colorectal tumors. By CRISPR/Cas9 genome editing tools, we simultaneously redirected T-cell specificity employing a novel T-cell receptor targeting the HER-2 antigen, and disrupted CD39, thus generating triple-knockout engineered lymphocytes. We showed that the absence of CD39 confers HER2-specific T cells a functional advantage in eliminating HER2+ patient-derived organoids, starring the relevance of the CD39 axis for further exploitation in adoptive T-cell therapy strategies to treat primary and metastatic colorectal cancer.

2023-07-12 | GSE200130 | GEO

RNA-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

Project description:RNA-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

| PRJNA1000918 | ENA

ATAC-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

Project description:ATAC-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

| PRJNA1000916 | ENA